Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy

Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Roche will speed up the development of its obesity programs, seeking to differentiate itself in the market.

Scroll to Top